Comparison of the effectiveness, safety and tolerability of Perampanel and Levetiracetam as monotherapy in Chinese patients with focal‐onset seizures: A single‐center, ambispective, open‐label, real‐world observational study

Documenti analoghi

• Perampanel monotherapy in pediatric epilepsy: Emphasizing the need for comprehensive safety evaluation
  di: Gabriel Christian de Farias Morais, et al.
  Pubblicazione: (2025)
• Long‐term safety and efficacy of adjunctive lacosamide in the treatment of generalized onset tonic–clonic seizures: An open‐label extension trial
  di: David G. Vossler, et al.
  Pubblicazione: (2024)
• Clinical efficacy and safety of perampanel monotherapy as primary anti‐seizure medication in the treatment of pediatric epilepsy: A single‐center, prospective, observational study
  di: Yanxia Gu, et al.
  Pubblicazione: (2024)
• Long‐term safety and efficacy of adjunctive perampanel in pediatric patients (ages 4 to <12 years) with inadequately controlled focal‐onset seizures or generalized tonic–clonic seizures
  di: Robert Flamini, et al.
  Pubblicazione: (2025)
• Efficacy and Safety of adjunctive Perampanel in a prospective, real‐world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal‐onset Epilepsy: Study 508
  di: Sangeeta Ravat, et al.
  Pubblicazione: (2024)